Free Trial

GeneDx Q1 2024 Earnings Report

GeneDx logo
$77.40 +2.10 (+2.79%)
(As of 12/20/2024 05:31 PM ET)

GeneDx EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A

GeneDx Revenue Results

Actual Revenue
$62.42 million
Expected Revenue
$49.80 million
Beat/Miss
Beat by +$12.62 million
YoY Revenue Growth
N/A

GeneDx Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

GeneDx Earnings Headlines

The top five midcap stocks of 2024
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
GeneDx Rides Revenue Surge, But Valuation Risks Loom
GeneDx expands access to exome testing for pediatric epilepsy patients
See More GeneDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeneDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your email.

About GeneDx

GeneDx (NASDAQ:WGS), through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

View GeneDx Profile

More Earnings Resources from MarketBeat

Upcoming Earnings